These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35968319)

  • 1. Consensus on early detection of disease progression in patients with multiple sclerosis.
    Meca-Lallana JE; Casanova B; Rodríguez-Antigüedad A; Eichau S; Izquierdo G; Durán C; Río J; Hernández MÁ; Calles C; Prieto-González JM; Ara JR; Uría DF; Costa-Frossard L; García-Merino A; Oreja-Guevara C
    Front Neurol; 2022; 13():931014. PubMed ID: 35968319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey.
    Alvarez E; Nair KV; Gorritz M; Bartolome L; Maloney H; Ding Y; Golan T; Wade RL; Kumar R; Su W; Shah R; Russo P
    Mult Scler Relat Disord; 2021 May; 50():102858. PubMed ID: 33799068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians' and patients' views.
    Ziemssen T; Tolley C; Bennett B; Kilgariff S; Jones E; Pike J; Tomic D; Piani-Meier D; Lahoz R
    Mult Scler Relat Disord; 2020 Feb; 38():101861. PubMed ID: 31865132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
    Boyko A; Therapontos C; Horakova D; Szilasiová J; Kalniņa J; Kolontareva J; Gross-Paju K; Selmaj K; Sereike I; Milo R; Gabelić T; Rot U
    Mult Scler Relat Disord; 2021 May; 50():102778. PubMed ID: 33592384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results from SPECTRUM: A survey of healthcare professionals to understand current diagnosis and management practices for secondary progressive multiple sclerosis in the United Kingdom.
    Duddy M; Wilkinson C; Medhurst S; Rhys K
    Mult Scler Relat Disord; 2021 Oct; 55():103174. PubMed ID: 34399317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study.
    Ziemssen T; Piani-Meier D; Bennett B; Johnson C; Tinsley K; Trigg A; Hach T; Dahlke F; Tomic D; Tolley C; Freedman MS
    J Med Internet Res; 2020 Feb; 22(2):e16932. PubMed ID: 32049062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary progressive multiple sclerosis: A national consensus paper on diagnostic criteria.
    Ciron J; Gueguen A; Al Khedr A; Bourre B; Clavelou P; Defer G; Durand-Dubief F; Labauge P; Ouallet JC; Pittion Vouyovitch S; Tourbah A; Vermersch P
    Rev Neurol (Paris); 2022 Dec; 178(10):1098-1104. PubMed ID: 36180289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus for the Early Identification of Secondary Progressive Multiple Sclerosis in Portugal: a Delphi Panel.
    Sá MJ; Basílio C; Capela C; Cerqueira JJ; Mendes I; Morganho A; Correia de Sá J; Salgado V; Martins Silva A; Vale J; Sousa L
    Acta Med Port; 2023 Mar; 36(3):167-173. PubMed ID: 36735763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.
    Kopp TI; Bramow S; Illes Z; Kant M; Kristensen C; Rasmussen PV; Sellebjerg F; Magyari M
    Mult Scler Relat Disord; 2021 Nov; 56():103319. PubMed ID: 34666241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary Progressive Multiple Sclerosis: New Insights.
    Cree BAC; Arnold DL; Chataway J; Chitnis T; Fox RJ; Pozo Ramajo A; Murphy N; Lassmann H
    Neurology; 2021 Aug; 97(8):378-388. PubMed ID: 34088878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neuropsychological and MRI diagnostics in secondary progressive multiple sclerosis].
    Penner IK; Gass A; Schreiber H; Wattjes MP
    Nervenarzt; 2021 Dec; 92(12):1293-1301. PubMed ID: 33891150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study.
    Uphaus T; Steffen F; Muthuraman M; Ripfel N; Fleischer V; Groppa S; Ruck T; Meuth SG; Pul R; Kleinschnitz C; Ellwardt E; Loos J; Engel S; Zipp F; Bittner S
    EBioMedicine; 2021 Oct; 72():103590. PubMed ID: 34571362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
    Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
    J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Argentinean consensus guidelines on the identification and clinical care of secondary progressive multiple sclerosis].
    Cristiano E; Patrucco L; Ysrraelit MC; Alonso R; Balbuena ME; Ballario C; Barboza AG; Bestoso S; Burgos M; Cáceres FJ; Carrá A; Carnero-Contentti E; Deri N; Fernández-Liguori N; Garcea O; Hryb JP; Jacobo M; Kohler E; Luetic GG; Mainella C; Menichini ML; Míguez J; Nofal PG; Piedrabuena R; Rugilo C; Saladino ML; Silva BA; Silva E; Sinay V; Tavolini D; Tkachuk VA; Villa A; Vrech C; Rojas JI
    Rev Neurol; 2021 Jan; 72(1):23-32. PubMed ID: 33378076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Difficulty in identification of patients with active secondary progressive multiple sclerosis by clinical classification tools.
    Klinsing S; Yalachkov Y; Foerch C
    Eur J Neurol; 2022 Apr; 29(4):1100-1105. PubMed ID: 34939266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis.
    Katz Sand I; Krieger S; Farrell C; Miller AE
    Mult Scler; 2014 Oct; 20(12):1654-7. PubMed ID: 24493475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transition to secondary progressive multiple sclerosis: The consequences for patients and healthcare systems, a healthcare professional survey.
    Caseby SCL; Woodhouse FA; Montgomery SM; Kroes MA; Duddy ME
    Health Sci Rep; 2022 Jan; 5(1):e474. PubMed ID: 35229042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary progressive multiple sclerosis - from neuropathology to definition and effective treatment.
    Adamczyk-Sowa M; Adamczyk B; Kułakowska A; Rejdak K; Nowacki P
    Neurol Neurochir Pol; 2020; 54(5):384-398. PubMed ID: 33058113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: Multicenter study in Argentina.
    Rojas JI; Patrucco L; Alonso R; Garcea O; Deri N; Carnero Contentti E; Lopez PA; Pettinicchi JP; Caride A; Cristiano E
    Mult Scler; 2021 Apr; 27(4):579-584. PubMed ID: 32484381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.
    Inojosa H; Proschmann U; Akgün K; Ziemssen T
    J Neurol; 2021 Apr; 268(4):1210-1221. PubMed ID: 31363847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.